|
|
Affymax Reveals Receipt Of $30 Mln Milestone Payment From Takeda- Update - Stock Markets Review |
|
Stock Markets ReviewIt had two studies in dialysis patients dubbed EMERALD 1and EMERALD 2, and two other studies dubbed PEARL 1 and PEARL 2 in non-dialysis patients. ... |
|
|
Amgen's EPO Drugs Dodge a Bullet as Hematide Stumbles, but the Big Biotech's ... - BNET |
|
BNETA subgroup analysis of anemia patients not yet on dialysis showed more cardiovascular side effects with Hematide. In one trial, patients on Hematide needed ... |
|
SREH Launches Branding Initiative to Support Progressive Growth as Holdings Entity - MarketWatch (press release) |
|
MarketWatch (press release)... conference and news information focusing on Cardiology, Gastroenterology, Hematology, Nephrology, Oncology, Primary Care, Rheumatology and Urology. ... |
|
Janet Bick awarded Lifetime Achievement Award from the Ontario Renal Network - Canada NewsWire (press release) |
|
Canada NewsWire (press release)"The Ontario Renal Network exists today in large part to the energy and commitment Janet and others in the kidney disease community brought to the campaign ... |
|
Affymax(R) Receives $30 Million Milestone Payments for Database Lock of Phase ... - MarketWatch (press release) |
|
MarketWatch (press release)... to develop and commercialize Hematide(TM)/peginesatide, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients. ... |
|
|
|
|
<< Start < Prev 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 Next > End >>
|
|
Page 1502 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
